Najjar, Rayan
Mustelin, Tomas
Article History
Received: 13 June 2023
Accepted: 12 November 2023
First Online: 15 November 2023
Competing interests
: R.N. declares no competing interests. T.M. reports consulting fees from Bristol-Myers Squibb (BMS), Cugene, QiLu Biopharma, Miro Bio, and Rome Therapeutics. He serves on the Scientific Advisory Board of Rome Therapeutics, the Tri-Institutional Drug Discovery Institute (non-profit), and the University of Copenhagen LEO Skin Immunology Centre (non-profit).